The First EU Joint Clinical Assessment Wasn’t About Ojemda. It Was About Comparative Evidence.
The EU Joint Clinical Assessment process produced its first completed output in June 2026, with the…
Category News
Revlimid: How a Drug Lost Patent Protection Without Losing Pricing Power
Revlimid’s patent cliff did not follow the conventional script. When the first generic version of lenalidomide…
Global Pricing Innovations Announces Leadership Transition: New Chair of the Board
Global Pricing Innovations Announces Leadership Transition: New Chair of the Board
Key themes and takeaways from ISPOR 2023: Understanding how big data and AI will shape the market access and HEOR landscape
Key themes and takeaways from ISPOR 2023: Understanding how big data and AI will shape the…
Competition Is Coming: How Can You Prepare for Loss of Exclusivity?
In this webinar co-hosted by Model N and Global Pricing Innovations (GPI), you’ll learn how to mitigate the impact…
GPI to launch first and only rapid value assessment and price prediction platform at World EPA Congress
The risk and cost involved with drug development has expedited in recent years and will continue…
GPI launches new unique platform solution, GPI horizon
Monday 7th November 2022, London, UK – Global Pricing Innovations (GPI), a leader in price and market…
GPI announces major research presence at ISPOR
Tuesday 12th April, 2022, London UK – Global Pricing Innovations (GPI), a leader in market access and commercial…
